Actively Recruiting
Open-Label Extension Evaluating Long-Term Safety of Inclisiran in Children and Adults with Familial Hypercholesterolemia After Completing Pediatric ORION Studies
Led by Novartis Pharmaceuticals · Updated on 2026-09-18
195
Participants Needed
52
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia HeFH or HoFH who have previously completed specific pediatric ORION studies. This open-label, single arm, multicenter extension study aims to provide continued access to inclisiran treatment while monitoring its effects over an extended period. Participants who completed the ORION-16 or ORION-13 studies receive a fixed dose of inclisiran sodium 300 mg in solution form. Those who completed ORION-19 or ORION-20 receive inclisiran doses adjusted based on their body weight. The study involves ongoing administration of inclisiran to assess long-term treatment outcomes. During the study, participants are monitored for adverse events and serious adverse events from the first day up to approximately 1080 days. Researchers measure changes in LDL cholesterol levels compared to baseline from the previous studies. Participants will have regular visits and assessments to track safety, tolerability, and lipid changes throughout the study duration, which may last up to nearly three years.
CONDITIONS
Brief Title
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here